Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908031 | 0.93 | MAP3K12 (0.38) | MAP3K12SYKKHKMAPK1HSD17B10 | |
| SCHEMBL908380 | 0.89 | KHK (0.42) | MAP3K12SYKKHKMAPK1SCN9A | |
| SCHEMBL908551 | 0.89 | KHK (0.42) | MAP3K12SYKKHKMAPK1SCN9A | |
| SCHEMBL908406 | 0.89 | CXCR3 (0.37) | MAP3K12SYKKHKMAPK1HSD17B10 | |
| SCHEMBL908272 | 0.88 | KHK (0.39) | MAP3K12SYKKHKMAPK1SCN9A | |
| SCHEMBL907814 | 0.88 | MAP3K12 (0.37) | MAP3K12SYKKHKMAPK1HSD17B10 | |
| SCHEMBL12903125 | 0.88 | SYK (0.38) | MAP3K12SYKKHKMAPK1HSD17B10 | |
| SCHEMBL908055 | 0.86 | SYK (0.38) | MAP3K12SYKKHKTRPV1 | |
| SCHEMBL908953 | 0.86 | SYK (0.38) | MAP3K12SYKKHKTRPV1 | |
| SCHEMBL908056 | 0.86 | SYK (0.38) | MAP3K12SYKKHKTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | GPR88, PIGO, PRLHR | MAP3K12 2358/4885SYK 2213/4885KHK 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.